Invokana Canagliflozin 300 mg 30 tabs

Invokana medication is available in 100 mg and 300 mg coated tablets. The main active ingredient of this medicine is canagliflozin hemihydrate. One tablet of Invokana Canagliflozin 300 mg 30 tabs contains 300 mg of canagliflozin, 117.8 mg of lactose and at least 1 mmol of sodium.

Pharmaceutical form

The drug Invokana 300 mg is available in tablets of white color, coated with a protective shell, has the shape of a capsule 17 mm long. On one side there is an indented inscription “300”, and on the other “CFZ”.

Indications for use

Invokana is prescribed for the treatment of adults suffering from poorly controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. Also, the drug can be used for self-treatment, when there are contraindications or individual intolerance to metformin, or in complex treatment of diabetes with other drugs.

Dosage and administration

The recommended dosage is 100 mg per day. The drug Invokana Canagliflozin 300 mg 30 tabs is indicated for use in patients who have a glomerular filtration rate (GFR) of more than 60 ml / min, that is, requires careful glycemic control. The 300 mg tablet is taken once a day, the most preferred time is the period before the morning meal (10-20 minutes before breakfast). Swallow the pill whole with a minimum amount of water. Prescribe the drug should be with maximum caution and constant monitoring for people over 75 years old, with pronounced signs of physical exhaustion, impaired renal function. For patients with mild or moderate levels of liver failure, dosage adjustment is not required. In children up to 18 years of age, the effect of the drug is not fully understood at the current time, so taking is not recommended.

Contraindications and adverse reactions

Hypersensitivity to the active or auxiliary substance contained in the preparation. The effectiveness of canagliflozin is determined by the function of the kidneys, respectively, in patients with acute renal failure, the level of drug absorption will be close to zero. The mechanism of action of the drug accelerates the process of excretion of glucose in the urine, invoking osmotic diuresis, leading to a decrease in intravascular volume and a decrease in blood pressure. Mild dizziness and hypotension may be observed in the patient taking Invokana.

Diabetic ketoacidosis

A condition that poses a threat to the patient's life, in some cases, was observed in patients taking canagliflozin. The occurrence of diabetic ketoacidosis is not often associated with the level of sugar in the blood, if the patient has relevant symptoms, the drug should be stopped immediately.

Amputation of the limbs

This condition often occurs with patients with type 2 diabetes. In patients taking canagliflozin, this risk is approximately doubled (the mechanism of action of risk factors is not fully understood). When skin ulcers, osteomyelin, gangrene appear on the lower limbs, Invokan's administration should be discontinued.

Interaction with other drugs

Intake of Invokana in combination with diuretics can enhance their action, which will contribute to dehydration. In combination with insulin, the drug can provoke hypoglycemia, so the insulin dose should be reduced or it should be used stimulants of its secretion in the body. Reduction of the effectiveness of Invokan is observed while it is being taken with enzyme preparations. Canagliflozin enhances the action of cardiac glycosides, in particular digoskin, the simultaneous use of two drugs should be continuously monitored by the patient.